AstraZeneca – media

Alchemab to collaborate with AstraZeneca on prostate cancer research

Cambridge-based biotech company Alchemab has announced a new collaboration with British pharma AstraZeneca (AZ), aiming to accelerate research for prostate cancer. As part of the collaboration, Alchemab and AZ will collaborate on a proof-of-concept study to improve understanding of the ‘fundamental biology’ of prostate cancer. Alchemab will utilise its novel drug discovery platform as a diagnostic tool through the identification of disease biomarkers, with the potential to inform the development of new antibody-based medications. Under the agreement, Alchemab will sequence and explore antibody repertoires in patient samples gathered from a clinical trial of an undisclosed immuno-oncology agent within AZ’s pipeline. Alchemab may also be able to identify antibody sequence patterns that could be used as biomarkers for early detection and patient stratification by classifying patients into two groups – responders and non-responders. The overall purpose of the collaboration is to identify novel and disease-relevant antibodies which may generate therapeutic insights into ...
- Source: drugdu
- 379
- May 7, 2021
AstraZeneca
AZ’s Farxiga Gets FDA Priority Review For Heart Failure

AstraZeneca has got off to a strong start in 2020, with the FDA granting a fast review for its diabetes drug Farxiga in heart failure and China approving Lokelma for hyperkalemia.
- Source: https://scrip.pharmaintelligence.informa.com/SC141424/AZs-Farxiga-Gets-FDA-Priority-Review-For-Heart-Failure
- 1,446
- January 8, 2020
AstraZeneca Farxiga FDA Lokelma
Fasenra Granted US Orphan Drug Designation for Eosinophilic Oesophagitis

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis (EoE). EoE is a rare, chronic, inflammatory disease that occurs when eosinophils, a type of white blood cell, accumulate in the oesophagus causing injury and inflammation. The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. About Fasenra Fasenra (benralizumab) is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death). Fasenra is AstraZeneca’s first respiratory biologic, now approved as an add-on maintenance treatment in severe eosinophilic asthma in the US, EU, Japan and other countries, with further regulatory reviews ongoing. In June 2019, the European Medicines ...
- Source: drugdu
- 773
- October 8, 2019
AstraZeneca Orphan Drug
Orphan Designation Granted to AZ and MSD’s Neurofibromatosis Drug

AstraZeneca and MSD's neurofibromatosis type 1 (NF1) drug, selumetinib, a MEK 1/2 inhibitor, receives orphan designation by the EMA.
- Source: PharmaTimes
- 764
- August 7, 2018
AstraZeneca neurofibromatosis New Approvals
Filing Lawsuit Against Drugmakers for Funding Terrorism

Last year, around 100 veterans filed a bombshell lawsuit against several drugmakers, by accusing that they funded terrorism by paying high bribes to win contracts with the Iraqi Ministry of Health. At present, the Department of Justice is investigating similar accusations, as per AstraZeneca securities filing which says that it's part of the probe.
- Source: FiercePharma
- 1,074
- August 3, 2018
AstraZeneca Company Insight pharmaceutical
AstraZeneca’s Durvalumab Receives Go-Ahead from DCGI to Market in India

Last Friday, pharma giant AstraZeneca announced that it had received the go-ahead from the Drug Controller General of India (DCGI) to import and market durvalumab (ImfinziTM) in India. The receipt of this permission paves the way for the launch of durvalumab (ImfinziTM) in India. Durvalumab which is a patented drug of Astra-Zeneca, received permission in India to provide treatment for patients with unresectable non-small cell lung cancer and metastatic urothelial carcinoma.
- Source: United News of India
- 2,561
- June 26, 2018
AstraZeneca cancer India New Approvals
Lynparza and Zytiga Combo Effective Against Prostate Cancer

Along with new drug partner Merck, the British drugmaker displayed results showing that adding Lynparza to Johnson & Johnson prostate cancer fighter Zytiga was a more potent disease-fighter than Zytiga alone. As compared to a time-frame of 8.2 months for solo Zytiga, the combo effectively prevented disease progression for 13.8 months.
- Source: Ddu
- 769
- June 6, 2018
AstraZeneca Clinical Trials Company Insight prostate cancer
R&D for organ-on-a-chip tech by AstraZeneca and Emulate.

AstraZeneca has collaborated with Emulate integrate an organ-on-a-chip technology into the R&D program of the pharma giant. It is meant to expedite the technology’s development within the company.
- Source: Ddu
- 777
- May 17, 2018
AstraZeneca Researches
Lynparza tablets (ovarian cancer) given go-ahead by European regulators

With a view to widening the scope of treatment for ovarian cancer patients, EU regulators have greenlighted MSD’s Lynparza and stamped approval for a new dosing regimen and tablet formulation for AstraZeneca.
- Source: drugdu
- 759
- May 10, 2018
AstraZeneca cancer New Approvals pharma
AstraZeneca continues yard-sale strategy with $538M Seroquel rights deal

AstraZeneca is back at it again with asset sales. The company, which has taken some flak for a series of deals to offload asset rights, inked an agreement with Luye Pharma for legacy antipsychotic Seroquel and an extended-release version.
- Source: fiercepharma
- 683
- May 10, 2018
AstraZeneca Seroquel

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.